Published in J Immunol on April 15, 1986
Independent regulation of tumor necrosis factor and lymphotoxin production by human peripheral blood lymphocytes. J Exp Med (1987) 4.54
A mouse model for investigating the molecular pathogenesis of adenovirus pneumonia. Proc Natl Acad Sci U S A (1991) 3.21
Production of tumor necrosis factor and other cytokines by astrocytes stimulated with lipopolysaccharide or a neurotropic virus. Proc Natl Acad Sci U S A (1989) 2.56
Interleukin-1 and tumor necrosis factor alpha can be induced from mononuclear phagocytes by human immunodeficiency virus type 1 binding to the CD4 receptor. J Virol (1989) 2.42
Malarial parasites induce TNF production by macrophages. Immunology (1988) 2.42
Functional complementation of the adenovirus E1B 19-kilodalton protein with Bcl-2 in the inhibition of apoptosis in infected cells. J Virol (1994) 2.14
Inhibition of Chlamydia trachomatis growth by recombinant tumor necrosis factor. Infect Immun (1988) 2.04
Concentrations of interleukin 6 and tumour necrosis factor in serum and stools of children with Shigella dysenteriae 1 infection. Gut (1993) 1.98
Pathogenesis of malaria and clinically similar conditions. Clin Microbiol Rev (2004) 1.87
Interferon gamma and lymphotoxin or tumor necrosis factor act synergistically to induce macrophage killing of tumor cells and schistosomula of Schistosoma mansoni. J Exp Med (1987) 1.75
Coordinate viral induction of tumor necrosis factor alpha and interferon beta in human B cells and monocytes. Proc Natl Acad Sci U S A (1989) 1.72
Beta interferon subtype 1 induction by tumor necrosis factor. Mol Cell Biol (1989) 1.67
Regulation of human immunodeficiency virus type 1 and cytokine gene expression in myeloid cells by NF-kappa B/Rel transcription factors. Microbiol Rev (1995) 1.63
Production of tumor necrosis factor alpha and interleukin 1 beta by monocytic cells infected with human immunodeficiency virus. J Clin Invest (1989) 1.61
Stimulus-specific assembly of enhancer complexes on the tumor necrosis factor alpha gene promoter. Mol Cell Biol (2000) 1.52
Induction of apoptosis by paramyxovirus simian virus 5 lacking a small hydrophobic gene. J Virol (2003) 1.40
Tumor necrosis factor alpha has a protective role in a murine model of systemic candidiasis. Infect Immun (1994) 1.37
Human immunodeficiency virus does not induce interleukin-1, interleukin-6, or tumor necrosis factor in mononuclear cells. J Virol (1990) 1.28
Reversion of the antichlamydial effect of tumor necrosis factor by tryptophan and antibodies to beta interferon. Infect Immun (1989) 1.28
Alveolar macrophages in AIDS patients: increased spontaneous tumour necrosis factor-alpha production in Pneumocystis carinii pneumonia. Clin Exp Immunol (1990) 1.23
Local production of tumor necrosis factor encoded by recombinant vaccinia virus is effective in controlling viral replication in vivo. Proc Natl Acad Sci U S A (1991) 1.22
Human granulocyte-macrophage colony-stimulating factor induces expression of the tumor necrosis factor gene by the U937 cell line and by normal human monocytes. J Clin Invest (1987) 1.18
Induction of tumor necrosis factor alpha by spherules of Coccidioides immitis. Infect Immun (1989) 1.13
Tumor necrosis factor alpha promotes replication and pathogenicity of rat cytomegalovirus. J Virol (1994) 1.05
Engagement of tumor necrosis factor mRNA by an endotoxin-inducible cytoplasmic protein. Mol Med (1996) 1.04
Induction of tumor necrosis factor by Legionella pneumophila. Infect Immun (1987) 1.00
Sendai virus induces high levels of tumor necrosis factor mRNA in human peripheral blood leukocytes. Nucleic Acids Res (1986) 0.95
HIV-1 induces tumour necrosis factor and IL-1 gene expression in primary human macrophages independent of productive infection. Clin Exp Immunol (1994) 0.94
Human immunodeficiency virus-1 infection of macrophages in vitro neither induces tumor necrosis factor (TNF)/cachectin gene expression nor alters TNF/cachectin induction by lipopolysaccharide. J Clin Invest (1990) 0.88
A protective role of platelet-activating factor in murine candidiasis. Infect Immun (1997) 0.87
Tumour necrosis factor production in fulminant hepatic failure: relation to aetiology and superimposed microbial infection. Clin Exp Immunol (1990) 0.85
Cytokine induction in human coccidioidomycosis. Infect Immun (1994) 0.84
Differential induction of tumor necrosis factor alpha in ovine pulmonary alveolar macrophages following infection with Corynebacterium pseudotuberculosis, Pasteurella haemolytica, or lentiviruses. Infect Immun (1991) 0.83
Cytokine regulation by virus infection: bovine viral diarrhea virus, a flavivirus, downregulates production of tumor necrosis factor alpha in macrophages in vitro. J Virol (1996) 0.82
Tumour necrosis factor triggers granulocytes to internalize complement-coated virus particles. Immunology (1991) 0.80
Vaccinia virus-regulated acute phase cytokine production in human fibroblasts, U937 cells and endothelium. Mediators Inflamm (1998) 0.80
2'-5' oligo-A-synthetase activity in bovine peripheral blood leukocytes and alveolar macrophages exposed to recombinant interferons and tumor necrosis factor-alpha. Can J Vet Res (1989) 0.75
Replication defective viral genomes exploit a cellular pro-survival mechanism to establish paramyxovirus persistence. Nat Commun (2017) 0.75
Involvement of MACH, a novel MORT1/FADD-interacting protease, in Fas/APO-1- and TNF receptor-induced cell death. Cell (1996) 9.93
Atomic structure of acetylcholinesterase from Torpedo californica: a prototypic acetylcholine-binding protein. Science (1991) 9.91
MAP3K-related kinase involved in NF-kappaB induction by TNF, CD95 and IL-1. Nature (1997) 6.53
Targeted disruption of the mouse Caspase 8 gene ablates cell death induction by the TNF receptors, Fas/Apo1, and DR3 and is lethal prenatally. Immunity (1998) 6.07
The p38 MAP kinase pathway signals for cytokine-induced mRNA stabilization via MAP kinase-activated protein kinase 2 and an AU-rich region-targeted mechanism. EMBO J (1999) 5.47
A novel protein that interacts with the death domain of Fas/APO1 contains a sequence motif related to the death domain. J Biol Chem (1995) 5.34
ESMO Consensus Guidelines for management of patients with colon and rectal cancer. a personalized approach to clinical decision making. Ann Oncol (2012) 5.32
Preferential effect of gamma interferon on the synthesis of HLA antigens and their mRNAs in human cells. Nature (1982) 3.74
Recruitment of the IKK signalosome to the p55 TNF receptor: RIP and A20 bind to NEMO (IKKgamma) upon receptor stimulation. Immunity (2000) 3.61
Stabilization of the bioactivity of tumor necrosis factor by its soluble receptors. J Exp Med (1992) 3.37
Interferon-dependent induction of mRNA for the major histocompatibility antigens in human fibroblasts and lymphoblastoid cells. Proc Natl Acad Sci U S A (1982) 3.11
Two tumor necrosis factor-binding proteins purified from human urine. Evidence for immunological cross-reactivity with cell surface tumor necrosis factor receptors. J Biol Chem (1990) 2.99
Two interferon mRNAs in human fibroblasts: in vitro translation and Escherichia coli cloning studies. Proc Natl Acad Sci U S A (1980) 2.88
Self-association of the "death domains" of the p55 tumor necrosis factor (TNF) receptor and Fas/APO1 prompts signaling for TNF and Fas/APO1 effects. J Biol Chem (1995) 2.78
The death domain: a module shared by proteins with diverse cellular functions. Trends Biochem Sci (1995) 2.70
TNF stimulates expression of mouse MHC class I genes by inducing an NF kappa B-like enhancer binding activity which displaces constitutive factors. EMBO J (1989) 2.65
Induction of interleukin-8 synthesis integrates effects on transcription and mRNA degradation from at least three different cytokine- or stress-activated signal transduction pathways. Mol Cell Biol (1999) 2.39
Tumor necrosis factor in familial Mediterranean fever. Am J Med (1991) 2.37
A tumor necrosis factor-binding protein purified to homogeneity from human urine protects cells from tumor necrosis factor toxicity. J Biol Chem (1989) 2.35
Soluble cytokine receptors are present in normal human urine. J Exp Med (1989) 2.24
Antibodies to a soluble form of a tumor necrosis factor (TNF) receptor have TNF-like activity. J Biol Chem (1990) 2.12
Thalidomide as salvage therapy for VAD-refractory multiple myeloma prior to autologous PBSCT. Bone Marrow Transplant (2002) 2.06
Inhibition of Chlamydia trachomatis growth by recombinant tumor necrosis factor. Infect Immun (1988) 2.04
Sensitization and desensitization to lethal effects of tumor necrosis factor and IL-1. J Immunol (1988) 2.02
Elevated tumour necrosis factor-alpha (TNF-alpha) biological activity in psoriatic skin lesions. Clin Exp Immunol (1994) 1.83
Epstein-Barr virus-transforming protein latent infection membrane protein 1 activates transcription factor NF-kappaB through a pathway that includes the NF-kappaB-inducing kinase and the IkappaB kinases IKKalpha and IKKbeta. Proc Natl Acad Sci U S A (1998) 1.81
Increased levels of soluble tumor necrosis factor receptors in the sera and synovial fluid of patients with rheumatic diseases. Arthritis Rheum (1992) 1.74
Immunocytochemical analysis of tumor necrosis factor and its receptors in Parkinson's disease. Neurosci Lett (1994) 1.73
CASH, a novel caspase homologue with death effector domains. J Biol Chem (1997) 1.72
Differential regulation of HLA-DR mRNAs and cell surface antigens by interferon. EMBO J (1983) 1.71
Increased serum levels of soluble receptors for tumor necrosis factor in cancer patients. Cancer Res (1991) 1.68
Preparations of lymphotoxin induce resistance to their own cytotoxic effect. J Immunol (1984) 1.64
Caspase-8 deficiency facilitates cellular transformation in vitro. Cell Death Differ (2008) 1.64
CD27, a member of the tumor necrosis factor receptor superfamily, activates NF-kappaB and stress-activated protein kinase/c-Jun N-terminal kinase via TRAF2, TRAF5, and NF-kappaB-inducing kinase. J Biol Chem (1998) 1.64
Assay of an interferon-induced enzyme in white blood cells as a diagnostic aid in viral diseases. Lancet (1981) 1.59
Calcium and the exportable protein in rat parotid gland. Parallel subcellular distribution and concomitant secretion. Eur J Biochem (1971) 1.52
Purification and crystallization of a dimeric form of acetylcholinesterase from Torpedo californica subsequent to solubilization with phosphatidylinositol-specific phospholipase C. J Mol Biol (1988) 1.51
Endoscopic submucosal resection with double ligation technique for treatment of small rectal carcinoid tumors. Endoscopy (2006) 1.49
Structures of recombinant native and E202Q mutant human acetylcholinesterase complexed with the snake-venom toxin fasciculin-II. Acta Crystallogr D Biol Crystallogr (2000) 1.47
Retroviral gene transfer into primary hepatocytes: implications for genetic therapy of liver-specific functions. Proc Natl Acad Sci U S A (1987) 1.44
Systemic leakage and side effects of tumor necrosis factor alpha administered via isolated limb perfusion can be manipulated by flow rate adjustment. Arch Surg (1995) 1.42
Identification of a cell protein (FIP-3) as a modulator of NF-kappaB activity and as a target of an adenovirus inhibitor of tumor necrosis factor alpha-induced apoptosis. Proc Natl Acad Sci U S A (1999) 1.42
Marriage: a 19th century French method for the prevention of syphilis: reflections on the control of AIDS. Int J Dermatol (1993) 1.41
[Thalidomide and thrombosis]. Ann Dermatol Venereol (2000) 1.40
Cytoplasmic truncation of the p55 tumour necrosis factor (TNF) receptor abolishes signalling, but not induced shedding of the receptor. EMBO J (1992) 1.39
Genome-wide copy number variation analysis in attention-deficit/hyperactivity disorder: association with neuropeptide Y gene dosage in an extended pedigree. Mol Psychiatry (2010) 1.33
Variation in serum levels of the soluble TNF receptors among healthy individuals. Lymphokine Cytokine Res (1992) 1.33
TNF-alpha binds to the N-terminal domain of fibronectin and augments the beta 1-integrin-mediated adhesion of CD4+ T lymphocytes to the glycoprotein. J Immunol (1994) 1.32
Reversion of the antichlamydial effect of tumor necrosis factor by tryptophan and antibodies to beta interferon. Infect Immun (1989) 1.28
Monitoring of interferon therapy by assay of (2'--5') oligo-isoadenylate synthetase in human peripheral white blood cells. J Interferon Res (1981) 1.27
Increase of vulnerability to lymphotoxin in cells infected by vesicular stomatitis virus and its further augmentation by interferon. Cell Immunol (1985) 1.26
Shedding kinetics of soluble tumor necrosis factor (TNF) receptors after systemic TNF leaking during isolated limb perfusion. Relevance to the pathophysiology of septic shock. J Clin Invest (1998) 1.24
Stimulation of guanylate cyclase of fibroblasts by free fatty acids. J Biol Chem (1976) 1.24
Thymic deficiency in Down's syndrome. Pediatrics (1979) 1.23
A potential mechanism of "cross-talk" between the p55 tumor necrosis factor receptor and Fas/APO1: proteins binding to the death domains of the two receptors also bind to each other. J Exp Med (1996) 1.23
Inhibition of tumor necrosis factor alpha (TNFalpha) activity in rat brain is associated with cerebroprotection after closed head injury. J Cereb Blood Flow Metab (1996) 1.23
Septicemia caused by the gram-negative bacterium CDC IV c-2 in an immunocompromised human. J Clin Microbiol (1986) 1.22
Studies on T cell subsets and functions in leprosy. Clin Exp Immunol (1981) 1.22
Unusual phenotypes of human inducer T cells as measured by OKT4 and related monoclonal antibodies. J Immunol (1981) 1.18
Non-parallel transport of membrane proteins and content proteins during assembly of the secretory granule in rat parotid gland. Biochim Biophys Acta (1975) 1.17
Evaluation of the human interferon system in viral disease. Clin Exp Immunol (1981) 1.17
A casein kinase I motif present in the cytoplasmic domain of members of the tumour necrosis factor ligand family is implicated in 'reverse signalling'. EMBO J (1999) 1.17
Biogenesis of chloroplast membranes. IX. Development of photophosphorylation and proton pump activities in greening Chlamydomonas reinhardi y-I as measured with an open-cell preparation. Biochim Biophys Acta (1972) 1.15
Down regulation of the receptors for tumor necrosis factor by interleukin 1 and 4 beta-phorbol-12-myristate-13-acetate. J Immunol (1987) 1.12
The interferon-induced enzyme oligo-isoadenylate synthetase: rapid determination of its in vitro products. Anal Biochem (1981) 1.10
Self-association of chicken gizzard filamin and heavy merofilamin. Biochemistry (1980) 1.09
Filamin-actin interaction. Dissociation of binding from gelation by Ca2+-activated proteolysis. J Biol Chem (1978) 1.09
Circulating plasma receptors for tumour necrosis factor in Malawian children with severe falciparum malaria. Cytokine (1993) 1.09
Stress-activated protein kinase/Jun N-terminal kinase is required for interleukin (IL)-1-induced IL-6 and IL-8 gene expression in the human epidermal carcinoma cell line KB. J Biol Chem (1998) 1.08
Structural requirements for inducible shedding of the p55 tumor necrosis factor receptor. J Biol Chem (1994) 1.08
Metastatic cutaneous Crohn's disease in a child. J Pediatr Gastroenterol Nutr (1998) 1.08
Tumor necrosis factor in middle ear effusions. Arch Otolaryngol Head Neck Surg (1988) 1.08
Cachectin/tumour-necrosis-factor production by cancer patients. Lancet (1985) 1.08
Microtiter assay for acetylcholinesterase. Anal Biochem (1987) 1.07
Pilot study of patient and caregiver out-of-pocket costs of allogeneic hematopoietic cell transplantation. Bone Marrow Transplant (2012) 1.07
Binding of human TNF-alpha to high-affinity cell surface receptors: effect of IFN. Immunol Lett (1986) 1.06
Increased expression of tumor necrosis factor-alpha receptors in the brains of patients with AIDS. J Acquir Immune Defic Syndr Hum Retrovirol (1995) 1.06
Elevated serum levels of soluble tumour necrosis factor receptors (sTNF-R) in patients with HIV infection. Clin Exp Immunol (1992) 1.05
Immune competence of newborn lymphocytes. Pediatrics (1980) 1.05